Published in Gene Therapy Weekly, February 13th, 1995
This mouse model carries a functional deficiency in the blood brain barrier. It is applicable to a wide range of central nervous system research, including neurotoxicology, drug transport, multi-drug resistance and studies of neurotrophic factor function. GenPharm acquired an exclusive world-wide license for this mouse strain and associated technologies from the Netherlands Cancer Institute (NCI).
Dr. Alfred H. Schinkel and his colleagues at the NCI developed the blood brain barrier deficient mouse...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.